135 related articles for article (PubMed ID: 19797237)
1. Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats.
Kemp W; Kompa A; Phrommintikul A; Herath C; Zhiyuan J; Angus P; McLean C; Roberts S; Krum H
Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G762-7. PubMed ID: 19797237
[TBL] [Abstract][Full Text] [Related]
2. Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol.
Zhang YG; Li YG; Liu BG; Wei RH; Wang DM; Tan XR; Bu DF; Pang YZ; Tang CS
Acta Pharmacol Sin; 2007 Jan; 28(1):36-43. PubMed ID: 17184580
[TBL] [Abstract][Full Text] [Related]
3. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension.
Kemp W; Krum H; Colman J; Bailey M; Yandle T; Richards M; Roberts S
Liver Int; 2007 Nov; 27(9):1232-9. PubMed ID: 17919235
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension.
Liu D; Chen J; Wang J; Zhang Z; Ma X; Jia J; Wang Y
Int J Mol Med; 2010 Jun; 25(6):845-51. PubMed ID: 20428787
[TBL] [Abstract][Full Text] [Related]
5. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.
Theodorakis NG; Wang YN; Wu JM; Maluccio MA; Sitzmann JV; Skill NJ
Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G792-9. PubMed ID: 19628654
[TBL] [Abstract][Full Text] [Related]
6. Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice.
Xu W; Wang LW; Shi JZ; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):300-8. PubMed ID: 19502172
[TBL] [Abstract][Full Text] [Related]
7. Antifibrogenic effects of tamoxifen in a rat model of periportal hepatic fibrosis.
Ryu SH; Chung YH; Lee JK; Kim JA; Shin JW; Jang MK; Park NH; Lee HC; Lee YS; Suh DJ
Liver Int; 2009 Feb; 29(2):308-14. PubMed ID: 18564211
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1.
Hirose T; Takahashi K; Mori N; Nakayama T; Kikuya M; Ohkubo T; Kohzuki M; Totsune K; Imai Y
Peptides; 2009 Jun; 30(6):1124-9. PubMed ID: 19463745
[TBL] [Abstract][Full Text] [Related]
10. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
11. Salviae miltiorrhizae ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats.
Wang H; Chen XP; Qiu FZ
Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):391-6. PubMed ID: 14599946
[TBL] [Abstract][Full Text] [Related]
12. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy.
Tzanidis A; Hannan RD; Thomas WG; Onan D; Autelitano DJ; See F; Kelly DJ; Gilbert RE; Krum H
Circ Res; 2003 Aug; 93(3):246-53. PubMed ID: 12842917
[TBL] [Abstract][Full Text] [Related]
13. Increased circulating urotensin II in cirrhosis: potential implications in liver disease.
Kemp W; Roberts S; Krum H
Peptides; 2008 May; 29(5):868-72. PubMed ID: 17913301
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension.
Coll M; Genescà J; Raurell I; Rodríguez-Vilarrupla A; Mejías M; Otero T; Oria M; Esteban R; Guardia J; Bosch J; Martell M
J Hepatol; 2008 Jul; 49(1):43-51. PubMed ID: 18457899
[TBL] [Abstract][Full Text] [Related]
15. [Serum hyaluronic acid level: correlation with quantitative measurement of hepatic fibrosis in a cirrhotic rat model].
Kim MY; Baik SK; Jang YO; Suk KT; Kim JW; Kim HS; Cho MY; Choi SJ; Um SH; Han KH
Korean J Hepatol; 2008 Jun; 14(2):159-67. PubMed ID: 18617763
[TBL] [Abstract][Full Text] [Related]
16. Role of thromboxane A2 in early BDL-induced portal hypertension.
Yokoyama Y; Xu H; Kresge N; Keller S; Sarmadi AH; Baveja R; Clemens MG; Zhang JX
Am J Physiol Gastrointest Liver Physiol; 2003 Mar; 284(3):G453-60. PubMed ID: 12431905
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral dominant-negative soluble PDGFRβ improves hepatic collagen, systemic hemodynamics, and portal pressure in fibrotic rats.
Reichenbach V; Fernández-Varo G; Casals G; Oró D; Ros J; Melgar-Lesmes P; Weiskirchen R; Morales-Ruiz M; Jiménez W
J Hepatol; 2012 Nov; 57(5):967-73. PubMed ID: 22820479
[TBL] [Abstract][Full Text] [Related]
18. Effects of hepatotrophic factors on the liver after portacaval shunt in rats with portal hypertension.
Zhang ZT; Jiang P; Wang Y; Li JS; Xue JG; Zhou YZ; Yuan Z
Chin Med J (Engl); 2006 Oct; 119(20):1727-33. PubMed ID: 17097021
[TBL] [Abstract][Full Text] [Related]
19. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension.
Oberti F; Sogni P; Cailmail S; Moreau R; Pipy B; Lebrec D
Hepatology; 1993 Sep; 18(3):621-7. PubMed ID: 8359803
[TBL] [Abstract][Full Text] [Related]
20. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
